Renal Disorder

Theragnostics announced the FDA has granted its radiodiagnostic imaging drug NephroScan for marketing approval.

Eculizumab, which is only approved by the FDA for the treatment of three rare conditions, may be used frequently for off-label indications that lack strong scientific evidence, according to a study published in JAMA Internal Medicine.